As at Jul 25, 2024, the CORT stock has a price-to-earnings ratio of 30.32. This is based on the current EPS of $1.15 and the stock price of $34.87 per share. An increase of 11% has been recorded in the PE ratio compared to the average of 27.4 of the past four quarters.
The mean historical PE ratio of Corcept Therapeutics over the last nine years is 49.0. The current 30.32 price-to-earnings ratio is 38% less than the historical average. In the past nine years, CORT's PE ratio reached its highest point in the Jun 2016 quarter at 546, with a price of $5.46 and an EPS of $0.01. The Sep 2018 quarter saw the lowest point at 10.54, with a price of $14.02 and an EPS of $1.33.
Maximum annual increase: 92.62% in 2020
Maximum annual decrease: -84.73% in 2017
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 31.84 | 48.92% |
| 2022 | 21.38 | 4.75% |
| 2021 | 20.41 | -28.21% |
| 2020 | 28.43 | 92.62% |
| 2019 | 14.76 | -28.18% |
| 2018 | 20.55 | 29.73% |
| 2017 | 15.84 | -84.73% |
| 2016 | 103.71 | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
The current PE ratio of CORT is above its 3 and 5-year historical averages, but it is lower than the 10-year average.
When compared to its peers LLY and MRK, CORT's PE ratio is lower, but it is higher than JNJ's and NVS's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| JNJ Johnson & Johnson | 10.55 | $386.7B |
| NVS Novartis AG | 13.96 | $225.1B |
| CORT Corcept Therapeutics Inc | 30.96 | $3.71B |
| BMRN Biomarin Pharmaceutical Inc | 77.61 | $16.06B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| MRK Merck & Co Inc | 137.65 | $317.26B |
| MNKD Mannkind Corp | 146.25 | $1.59B |
| BMY Bristol Myers Squibb Co | N/A | $102.27B |
| PFE Pfizer Inc | N/A | $174.36B |
| ESPR Esperion Therapeutics Inc | N/A | $460.39M |
The price to earnings ratio for CORT stock is 30.32 as of Jul 25, 2024.
Over the last 3 years, the average PE ratio for CORT stock is 24.32.
Over the last 5 years, the average PE ratio for CORT stock is 22.71.
In the last nine years, the Jun 2016 quarter recorded the highest quarterly PE ratio at 546.
CORT's current price to earnings ratio is 38% below its 9-year historical average.
You can calculate the P/E ratio by dividing the most recent stock price by the trailing twelve months earnings per share(EPS). As of today (Jul 25, 2024), Corcept Therapeutics's stock price is $34.87. The earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $1.15. Therefore, Corcept Therapeutics's price to earnings ratio for today is 30.32. PE RATIO(30.32) = STOCK PRICE($34.87) / TTM EPS($1.15)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.